<P>&nbsp;</P> <P>&nbsp;</P> <P align=justify><STRONG><STRONG><A style="COLOR: #e02020" title="" href="http://www.fabentech.com/" target=_blank>Fab&#8217;entech</A></STRONG>, a biopharmaceutical company based in Lyon, has announced the launch of its first clinical trial against the <A style="COLOR: #e02020" title="" href="http://www.fabentech.com/emerging_diseases/emerging-diseases/h5n1-virus" target=_blank>H5N1 virus </A>in humans,</STRONG> the virus behind bird flu.&nbsp; Bertrand L&#233;pine, president and founder of the company, declares that &#8220;<EM>if the promising results obtained during tests on animals are confirmed, these immunoglobulins could be part of a new and specific approach to dealing with subjects potentially affected by the H5N1 virus</EM>.&#8221;</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>The clinical trial will take place in Singapore,</STRONG> since it is a region &#8220;that has one of the highest risks of the H5N1 virus spreading,&#8221; explains Bertrand L&#233;pine. Thanks to a perfectly controlled procedure using <A style="COLOR: #e02020" title="" href="http://www.sanofipasteur.com/" target=_blank>Sanofi Pasteur</A>&#8216;s&nbsp; (<A style="COLOR: #e02020" title="" href="http://www.sanofi.fr/l/fr/fr/index.jsp" target=_blank>Sanofi</A>&#8217;s vaccine division) recognized technology, and in collaboration with <A style="COLOR: #e02020" title="" href="http://www.p4-jean-merieux.inserm.fr/" target=_blank>Lyon&#8217;s Inserm-Jean M&#233;rieux Bio-safety level 4 laboratory</A>, <STRONG>Fab&#8217;entech can produce on an industrial scale the highly purified immunoglobulins necessary for neutralizing the virus.</STRONG></P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>Fab&#8217;entech is specialized in developing polyclonal antibodies specific to emerging infectious diseases.</STRONG> The company was created in 2009 in the <A style="COLOR: #e02020" title="" href="https://www.aderly.com/centre-recherche-et/developpement-france,p,21,EN.jsp" target=_blank>Gerland</A> district of Lyon, in the middle of <STRONG><STRONG><A style="COLOR: #e02020" title="" href="http://www.lyonbiopole.com/index.html" target=_blank>Lyonbiopole</A></STRONG>, a global competitiveness cluster specialized in infectious diseases. Fab&#8217;entech has deep roots in the Lyon region</STRONG> for its <A style="COLOR: #e02020" title="" href="https://www.aderly.com/pepiniere-entreprise/centre-recherche,p,16,EN.jsp" target=_blank>R&amp;D</A> and production activities, but the company concentrates mainly on <STRONG>export markets</STRONG>. Indeed, it targets all countries who suffer more and more urgently from a lack of satisfactory health care with which to protect their local, military and medical populations from the increasing risks of emerging infectious diseases.</P> <P align=justify></P>